Q-omics provides the consensus-scored TP53TG5 profile across patient tissues and cancer cell-line models. TP53TG5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TP53TG5 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TP53TG5 RNA expression shows 20,929 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, and UVM as cancer lineages where TP53TG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53TG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53TG5 survival associations across molecular data types. TP53TG5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53TG5 RNA expression–survival associations across cancer types. High TP53TG5 expression shows unfavorable associations in THCA, OV and LIHC, but favorable associations in HNSC, PAAD and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify THCA as the clearest survival context for TP53TG5 RNA expression.
This table summarizes TP53TG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TP53TG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53TG5 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and READ. The THCA box plot shows higher TP53TG5 RNA expression in normal versus tumor tissue (log2 FC = −0.560, t-test p < 0.001).
This table shows molecular features associated with TP53TG5 in patient tissues and cancer cell lines. In patient samples, TP53TG5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53TG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
